Feng Chi Biotech Corp (6744) Fair Value & Analysis
Healthcare · TW · Market cap 245M TWD
Fair value as of: Jun 24, 2026
Analysis
Feng Chi Biotech Corp (6744) currently trades at 14.50 TWD, while our model-based Fair Value estimate is 12.01 TWD — implying the stock looks roughly 17.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company was founded in 1992 and is based in Taipei, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Feng Chi Biotech Corp (6744) undervalued?
What is the fair value of 6744?
What is the quality score of 6744?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.